Dr. Melissa Reed -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Melissa Reed, a Oncology physician based in Greensboro, NC. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Melissa Reed has received $3,406.38 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Melissa Reed
- Medical Specialty: Oncology
- Practice Location: Greensboro, NC, North Carolina
- NPI Number: 1653936176
- Transparency Score: 50/100
- Payment Records Span: 2025-12-03 to 2025-12-03
Payment Summary
Dr. Melissa Reed has received a total of $3,406.38 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $3,406.38 per transaction.
- Total Payments Received: $3,406.38
- Number of Transactions: 1
- Average Payment: $3,406.38
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Oncology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Melissa Reed's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|
The largest payment category for Dr. Melissa Reed is Speaking & Education, accounting for 0% ($0.00) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Melissa Reed. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| AbbVie Inc | $3,406.38 | 1 |
Dr. Melissa Reed has a financial relationship with AbbVie Inc, receiving $3,406.38 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Melissa Reed. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Eylea -- Referenced in payment records from pharmaceutical companies to Dr. Melissa Reed
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Melissa Reed's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Melissa Reed, an Oncologist in Greensboro, NC, has received a total of $3,406.38 in pharmaceutical payments, with a single payment recorded. This payment originated from AbbVie Inc. and was designated for general purposes, with a future date of December 3, 2025. The total volume of payments received by Dr. Reed is notably low when compared to the average for oncologists. Oncology is a field where pharmaceutical companies invest significantly in research, development, and physician education, leading to higher average payment volumes. While specific peer data for Greensboro, NC, is not available, national averages for oncologists often show substantially higher figures, sometimes in the tens of thousands of dollars annually, encompassing various payment types like consulting fees, research grants, and speaking engagements. The sole identified relationship is with AbbVie Inc., a major pharmaceutical company with a significant presence in oncology drug development. This single, relatively modest payment from AbbVie Inc. does not, in itself, suggest a deep or extensive financial tie. The payment type is listed as 'general,' which is broad and could encompass various activities, but without further detail, it's difficult to ascertain the exact nature of the professional engagement. Given the single, future-dated, and general nature of this payment, it does not immediately suggest a pattern of routine professional activity that warrants significant concern. However, it is important to note that even small payments can potentially influence perceptions or decisions. For patients, these payments represent the financial interactions between physicians and the pharmaceutical industry. While such relationships can facilitate medical education and research, they also raise questions about potential conflicts of interest. Patients should be aware that their doctor may receive payments from companies whose drugs they prescribe. It is crucial for patients to have open and honest conversations with their healthcare providers about treatment options, understanding that recommendations should be based on the best available evidence and individual patient needs, rather than solely on financial incentives. Understanding the source and nature of any pharmaceutical payments can empower patients to engage more critically with their healthcare decisions.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Melissa Reed is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's pharmaceutical payment history, it's important to approach the information with a balanced perspective. Pharma relationships are common and can be beneficial for medical advancement and education. However, transparency is key to maintaining trust. At your next appointment, consider asking your doctor about their relationships with pharmaceutical companies. You might inquire if they receive any payments or have consulting roles, and how they ensure these relationships do not influence their treatment recommendations. Red flags to watch for include a doctor who seems overly enthusiastic about a particular drug without clear clinical justification, or who dismisses alternative treatments. While normal professional activities like attending educational conferences sponsored by drug companies are common, a pattern of frequent, high-value payments, especially for consulting or speaking, might warrant closer scrutiny. Evaluate your doctor's prescribing patterns by looking at whether they tend to prescribe newer, more expensive drugs when equally effective, less costly options exist. Remember, these payments do not automatically mean your doctor is providing substandard care, but they do highlight the importance of open communication and critical evaluation of treatment decisions.
Peer Comparison: How Dr. Melissa Reed Compares to Other Oncology Physicians
Dr. Reed's total pharmaceutical payment of $3,406.38 is significantly lower than the average for oncologists nationwide. While specific averages can fluctuate, oncologists often receive payments in the tens of thousands of dollars annually, reflecting the complex and research-intensive nature of cancer care. This doctor's profile, with a single payment, falls well below typical engagement levels seen in the specialty.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Melissa Reed in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| AbbVie Inc | $3,406.38 | general | Eylea | 2025-12-03 | Not Assessed |
Frequently Asked Questions About Dr. Melissa Reed's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Melissa Reed taking too much pharma money?
Dr. Reed's total pharmaceutical payment of $3,406.38 is relatively low, especially compared to national averages for oncologists, which can often reach tens of thousands of dollars annually. The single payment from AbbVie Inc. does not suggest an excessive financial reliance on pharmaceutical companies. While any payment warrants awareness, this amount, in isolation, is unlikely to be considered 'too much' in the context of the specialty.
What pharma companies pay Dr. Melissa Reed?
Dr. Melissa Reed has received one payment totaling $3,406.38 from AbbVie Inc. This is the only pharmaceutical company identified in the provided data for this physician.
Should I switch doctors because of pharma payments?
A single, relatively modest payment like the one received by Dr. Reed is generally not a reason to switch doctors. Consider the overall quality of care, your trust in the physician, and their communication style. If you observe a pattern of concerning prescribing habits or a lack of transparency, that might be a more significant factor than isolated payment data.
What kinds of payments does this doctor receive?
Based on the provided data, Dr. Reed received a single payment of $3,406.38 from AbbVie Inc. The payment type is categorized as 'general,' which is broad and does not specify if it was for consulting, speaking, meals, travel, or research. The payment breakdown shows zero for all specific categories, indicating the 'general' designation is not further itemized in this dataset.
How do these payments compare to other Oncology?
Dr. Reed's total payment of $3,406.38 is significantly lower than the average for oncologists. National averages often show oncologists receiving substantially more, reflecting the industry's investment in this specialty. This doctor's payment profile is well below the typical range for their field.
Do pharma payments affect prescribing quality?
Research suggests that even small financial incentives from pharmaceutical companies can subtly influence physician prescribing habits, potentially leading to increased use of the sponsoring company's drugs. However, this does not automatically equate to lower quality care. Many physicians maintain high ethical standards, and payments can support valuable professional development. The key is awareness and open communication between patient and doctor.
How can I verify this payment data?
You can verify this payment data by visiting the Centers for Medicare & Medicaid Services (CMS) 'Open Payments' website. This official government database allows you to search for physicians by name or NPI (National Provider Identifier) and view their reported financial relationships with the pharmaceutical and medical device industries.
Understanding This Doctor Payment Report
This transparency report for Dr. Melissa Reed is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Oncology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Melissa Reed's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Melissa Reed and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Oncology Specialty Payment Data -- See payment patterns for all oncology physicians
- North Carolina Physician Payments -- Browse pharmaceutical payments to physicians in North Carolina
- Oncology Physicians in North Carolina -- Compare Dr. Melissa Reed to peers in the same state and specialty
- AbbVie Inc Payment Profile -- View all payments made by Dr. Melissa Reed's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Melissa Reed's NPI (1653936176) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.